The application period is continuous: we will accept project proposals throughout the year.
Applications will be reviewed by medical and scientific experts. Decisions taken at these reviews will be communicated to the applicants.
The amount of money to be granted will depend on the complexity of the project, but will be limited to a maximum support of EUR 75,000 per project.
Linde Healthcare (the Healthcare division of the Linde Group) will treat all information submitted in applications as non-confidential. Accordingly, applicants are advised not to disclose information that applicants deem to be proprietary or confidential in their initial applications. To the extent that an evaluation of an application requires that confidential information is disclosed to Linde Healthcare, Linde Healthcare may consider entering into a non-disclosure agreement with the applicant. This will be determined on a case-by-case basis and Linde Healthcare may, in its sole discretion, determine that it is not in the best interest of Linde Healthcare to enter into a non-disclosure agreement relating to a specific applicant and/or a specific subject matter. In such cases, the application may be rejected without evaluation.
To the extent that the programme will involve interventional trials on humans, support will be provided as research grants and the applicant shall be fully responsible for compliance with legal requirements and ethical standards (such as the declaration of Helsinki) relating to clinical trials.
For other programmes, support will be provided as a grant on the condition that Linde Healthcare is granted a first right to negotiate rights to commercially exploit any novel technology on which the project is based.
Grantees will be required to submit interim progress reports as well as a final report after finalisation of the programme.